Limited Submission Funding Opportunities – updated 12/11/20

Please be aware that any grant that brings in less than 15% in indirect costs (IDC) will need to be supplemented up to the 15% equivalent by existing investigator or departmental sundry funds. Resolution of this issue must occur prior to submitting a proposal. Training fellowships from foundations, public charity, and non-profit organizations are excluded from this minimum IDC requirement.

For MGH investigators selected through a competitive process as the institutional nominee for any limited submission funding opportunities, in situations in which the grant will bring in less than 15% indirect cost (IDC), ECOR will cover the IDC gap up to a maximum of $50,000 per year. In order to optimize the distribution of limited ECOR funds across the MGH research community, it is expected that PIs and departments will work together to cover the remaining IDC shortfall.

This policy is only effective for those limited submission opportunities in which MGH is invited to submit its own nominee(s). This policy does not apply for those limited submission opportunities in which the MGH investigator must apply through HMS.

For further questions, please contact ECOR at ecor@mgh.harvard.edu

We ask that all MGH Investigators interested in applying for any limited submission award submit a Letter of Intent (see detailed instructions below) to the MGH Executive Committee on Research (ECOR) by the deadline indicated for each award to be considered to receive an institutional nomination.

Process
Submit a one- to two-page Letter of Intent (LOI) to the MGH Executive Committee on Research (ECOR) via email to ecor@mgh.harvard.edu. In addition to your LOI, please include an NIH Biosketch.

The letter of intent should include:
1. Name of the Principal Investigator with appropriate contact information
2. A descriptive title of the potential application
3. Brief description of the project
4. Brief description of why you specifically should be selected to receive institutional nomination for this award

In the event that there is more than one MGH investigator interested in applying for a limited submission award, the LOIs will be used to assess candidates and a review and selection process will take place.

If there is a limited submission funding opportunity you do not see listed below or you have any additional questions, please let us know at ecor@mgh.harvard.edu.

CURRENT OPPORTUNITIES

1. Kenya Community Grant Initiative – Data Collection Platform - NEW!
   https://www.grants.gov/web/grants/view-opportunity.html?oppId=330187
   MGH LOI Deadline: 12/16/21
   Sponsor Application Deadline: 1/01/21

PEPFAR Kenya recognizes the critical role that civil society organizations (CSOs) play toward achieving epidemic control in Kenya. To this end, PEPFAR Kenya is implementing a CSO community grant initiative (CGI) aimed at collecting patient and provider level input related to the quality of services provided at all PEPFAR sites. Therefore, to be successful in the community led monitoring project, PEPFAR needs a software company that can design an easily interoperable platform that will collect patient and provide feedback data. Survey questions to be shared with grant recipient by the CGI coordination mechanism
grantee. The CGI coordination mechanism will determine the survey questions/data to be collected from patients and providers based on the given context of the three pilot counties (Makueni, Kilifi, and Homabay) and also the needs and concerns of community members. Examples of the types of data that might be collected include information from beneficiaries about their experience with the health facility, information about barriers and enablers to access, retention in services, etc.

2. **Reducing Inequities in Cancer Outcomes through Community-Based Interventions on Social Determinants of Health – NEW!**

https://www.grants.gov/web/grants/view-opportunity.html?oppId=328316

MGH LOI Deadline: 12/29/20
Sponsor LOI Deadline: 1/11/21
Sponsor Application Deadline: 2/10/21

The purpose of this NOFO is to conduct evaluation research to build an evidence base of innovative, community-based interventions across multiple social determinants of health to reduce racial and ethnic disparities related to cancer outcomes. The purpose will be achieved through three (3) components.

- **Component A: Primary Cancer Prevention** – evaluation of the implementation, impact, and causal mechanisms of an intervention’s effect to reduce racial or ethnic inequities in cancer risk at the population level.
- **Component B: Cancer Screening** – evaluation of the implementation, impact, and causal mechanisms of an intervention’s effect to reduce racial or ethnic inequities in the receipt of appropriate screening services for breast, cervical, colorectal or lung cancer.
- **Component C: Health and Wellbeing of Cancer Survivors** – evaluation of the implementation, impact, and causal mechanisms of an intervention’s effect to reduce racial or ethnic inequities in the health and wellbeing of cancer survivors.

3. **NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Basic Experimental Studies with Humans Required)**


MGH LOI Deadline: 1/05/21
NIH Application Deadline: 2/26/21

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research career development beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

This Funding Opportunity Announcement is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should be submitted under this Funding Opportunity
Limited Submission Funding Opportunities – updated 12/11/20

Announcement (FOA) include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Applicants not planning an independent clinical trial or basic experimental study with humans, or proposing to gain research experience in a clinical trial or basic experimental study with humans led by another investigator, must apply to the 'Independent Clinical Trial Not Allowed' companion FOA, RFA-CA-20-056.

4. NCI Pathway to Independence Award for Outstanding for Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Not Allowed)
MGH LOI Deadline: 1/05/21
NIH Application Deadline: 2/26/21

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Fellows (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Under this FOA candidates are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary study to an ongoing clinical trial as lead investigator, should apply to the companion FOA (RFA-CA-20-057).

5. NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00 – Independent Clinical Trial Required)
MGH LOI Deadline: 1/05/21
NIH Application Deadline: 2/26/21

The purpose of the NCI Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00) program is to increase and maintain a strong cohort of new and talented, NCI-supported, independent investigators. This program is designed for postdoctoral fellows with research and/or clinical doctoral degrees who do not require an extended period of mentored research beyond their doctoral degrees. The objective of this award is to facilitate a timely transition of these fellows from their mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. The program will provide independent NCI research support during this transition to help awardees to launch competitive, independent research careers. Researchers in the scientific areas of data science and cancer control science are especially encouraged to apply.

This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a
6. Understanding the Cellular and Molecular Mechanisms of Gastroparesis in Adults and Children (R01 Clinical Trial Not Allowed)
MGH LOI Deadline: 1/12/21
NIH LOI Deadline: 2/03/21
NIH Application Deadline: 3/03/21

Since its establishment in 2006, the Gastroparesis Clinical Research Consortium (GpCRC), a multi-center coalition created and funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has made major advances to our understanding of the pathophysiology of Gastroparesis (Gp).

Through the establishment of the largest gastroparesis tissue repository in the United States, combined with detailed phenotypic data, the GpCRC is ideally suited to accelerate insights into the underlying cellular and molecular pathophysiology of the gastroparesis with the ultimate goal of developing therapeutic target(s).

This RFA invites investigators from several disciplines, including basic and translational research in areas of neurosciences, immunology, microbiology and physiology, to contribute new insights into the cellular and molecular mechanisms of Gastroparesis.